Miguel Angel García-Pérez

Dr. Miguel Angel García-Pérez

Department of Genetics, Faculty of Biology, University of Valencia, Spain
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2015 in Calcified Tissue International
Verified
Journal Article
Closed access
PDF file
LPLayla Panach
Layla Panach
DMDamián Mifsut
Damián Mifsut
JTJuan J. Tarín
Juan J. Tarín
ACAntonio Cano
Antonio Cano
Miguel Angel García-PérezMiguel Angel García-Pérez
Miguel Angel García-Pérez

1 June 2020 in Maturitas
Verified
Journal Article
Closed access
M. Luz Sanchez-SanchezM. Luz Sanchez-Sanchez
M. Luz Sanchez-Sanchez
AGAlicia García-Vigara
Alicia García-Vigara
JHJuan José Hidalgo-Mora
Juan José Hidalgo-Mora
Miguel Angel García-PérezMiguel Angel García-Pérez
Miguel Angel García-Pérez
JTJuan J. Tarín
Juan J. Tarín
ACAntonio Cano
Antonio Cano

1 February 2020 in Maturitas
Verified
Journal Article
Closed access
JHJuan José Hidalgo-Mora
Juan José Hidalgo-Mora
AGAlicia García-Vigara
Alicia García-Vigara
M. Luz Sanchez-SanchezM. Luz Sanchez-Sanchez
M. Luz Sanchez-Sanchez
Miguel Angel García-PérezMiguel Angel García-Pérez
Miguel Angel García-Pérez
JTJuan J. Tarín
Juan J. Tarín
ACAntonio Cano
Antonio Cano

1 August 1998 in Immunology
Verified
Journal Article
Closed access
LAL M Allende
L M Allende
Alfredo CorellAlfredo Corell
Alfredo Corell
JMJ Manzanares
J Manzanares
DMD Madruga
D Madruga
AMA Marcos
A Marcos
AVArnaiz‐ Villena
Arnaiz‐ Villena

28 January 2010 in Journal of Molecular Endocrinology
Verified
Journal Article
Open access
PDF file
ASAgua Sobrino
Agua Sobrino
POPilar J Oviedo
Pilar J Oviedo
Susana NovellaSusana Novella
Susana Novella
ALAndrés Laguna-Fernandez
Andrés Laguna-Fernandez
CBCarlos Bueno
Carlos Bueno
CHCARLOS HERMENEGILDO
CARLOS HERMENEGILDO
Estradiol (E2) acts on the endothelium to promote vasodilatation through the release of several compounds, including prostanoids, which are products of arachidonic acid metabolism. Among these, prostacyclin (PGI2) and thromboxane A2 (TXA2) exert opposite effects on vascular tone. The role of different estrogen receptors (ERs) in the PGI2/TXA2 balance, however, has not been fully elucidated. Our study sought to uncover whether E2 enhances basal production of PGI2 or TXA2 in cultured human umbilical vein endothelial cells (HUVECs), to analyze the enzymatic mechanisms involved, and to evaluate the different roles of both types of ERs (ERα and ERβ). HUVECs were exposed to E2, selective ERα (1,3,5-tris(4-hydroxyphenyl)-4-propyl-1h-pyrazole, PPT) or ERβ (diarylpropionitrile, DPN) agonists and antagonists (unspecific: ICI 182 780; specific for ERα: methyl-piperidino-pyrazole, MPP). PGI2 and TXA2 production was measured by ELISA. Expression of phospholipases, cyclooxygenases (COX-1 and COX-2), PGI2 synthase (PGIS), and thromboxane synthase (TXAS) was analyzed by western blot and quantitative RT-PCR. E2 (1–100 nM) dose dependently increased PGI2 production (up to 50%), without affecting TXA2 production. COX-1 and PGIS protein and gene expressions were increased, whereas COX-2, phospholipases, and TXAS expression remained unaltered. All these effects were mediated through ERα, since they were produced not only in the presence of E2, but also in that of PPT, while they were abolished in the presence of MPP. In conclusion, E2, acting through ERα, up-regulates COX-1 and PGIS expression, thus directing prostanoid balance toward increased PGI2 production.

1 February 2015 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
LSLucía Sanz-Salvador
Lucía Sanz-Salvador
Miguel Angel García-PérezMiguel Angel García-Pérez
Miguel Angel García-Pérez
JTJuan J Tarín
Juan J Tarín
ACAntonio Cano
Antonio Cano
Changes in bone density and bone markers suggest that pregnancy is associated with deterioration of bone mass in the mother. The metabolism of calcium resets to allow for the needs imposed by the building of the fetal skeleton. The fetus contributes to the process through the output of regulators from the placenta. Understanding of the whole process is limited, but some changes are unambiguous. There is an increase in the circulating levels of vitamin D, but its functional impact is unclear. Fetal parathyroid hormone (PTH) and PTH-related peptide (PTHrp) play an indirect role through support of a calcium gradient that creates hypercalcemia in the fetus. Placental GH, which increases up to the end of pregnancy, may exert some anabolic effects, either directly or through the regulation of the IGF1 production. Other key regulators of bone metabolism, such as estrogens or prolactin, are elevated during pregnancy, but their role is uncertain. An increase in the ratio of receptor activator of nuclear factor kappa B ligand (RANKL) to osteoprotegerin (OPG) acts as an additional pro-resorbing factor in bone. The increase in bone resorption may lead to osteoporosis and fragility fracture, which have been diagnosed, although rarely. However, the condition is transitory as long-term studies do not link the number of pregnancies with osteoporosis. Prevention is limited by the lack of identifiable risk factors. When fractures are diagnosed, rest, analgesics, or, when indicated, orthopedic intervention have demonstrated efficacy. Systemic treatment with anti-osteoporotic drugs is effective, but the potential harm to the fetus imposes caution in their use.